Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024)
Cellyan Biotechnology (HKPD) reported Long-Term Deferred Tax of $2.2 million for Q3 2024, up 71.54% quarter-over-quarter from $1.3 million in Q1 2024.
Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024) Analysis & Trends
Cellyan Biotechnology (HKPD) has 1 years of Long-Term Deferred Tax data on file, last reported at $2.2 million in Q3 2024.
- Long-Term Deferred Tax for Q3 2024 came in at $2.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $2.2 million (changed N/A YoY), and the FY2024 annual result was $1.3 million, changed N/A from the prior year.
- Long-Term Deferred Tax improved to $2.2 million in Q3 2024 per HKPD's latest filing, from $1.3 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $2.2 million in Q3 2024 and troughed at $1.3 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.26 Mn |